Cosela (trilaciclib) is a new FDA-approved oncology therapy manufactured by G1 Therapeutics
Cosela (trilaciclib) is a new FDA-approved oncology therapy manufactured by G1 Therapeutics
… New G1 Therapy Cosela (trilaciclib) is an important new therapy for oncology …

New oncology therapy indicated for use in the treatment of small cell lung cancer

John G. Baresky

The U.S. Food and Drug Administration (FDA) has approved a new oncology therapy developed by G1 Therapeutics. Cosela (trilaciclib) earned an indication from the FDA to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered before a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC).

G1 Therapeutics expects the product to be available to the marketplace in March 2021.

Cosela is the first and only FDA-approved therapy that helps proactively deliver multilineage myeloprotection to patients with extensive-stage small-cell lung cancer being treated with chemotherapy.

The product is a kinase inhibitor that…


Robert Davis New CEO At Merck
Robert Davis New CEO At Merck
… Merck names Robert Davis as new CEO …

Present Merck CEO Kenneth Frazier is retiring in June

John G. Baresky

Global pharmaceutical giant Merck (NYSE: MRK) has named Robert Davis as their next chief executive officer. Davis joined Merck as a chief financial officer in 2014. The company’s present CEO, Kenneth Frazier, is retiring in June.

Frazier has been a prolifically successful leader at Merck and is one of the few black Fortune 500 CEOs. Ken will continue to serve on Merck’s board of directors as executive chairman during the course of a transition period. …


ViiV Healthcare Launches New HIV Therapy Cabenuva
ViiV Healthcare Launches New HIV Therapy Cabenuva
… ViiV Healthcare Launches New HIV Therapy Cabenuva …

GlaxoSmithKline, Pfizer and Shionogi enterprise continues to advance its HIV-focused business mission and develop breakthrough treatments

John G. Baresky

ViiV Healthcare, a company exclusively devoted to the HIV/AIDs marketplace, has announced the FDA has approved its latest new injectable therapy combination Cabenuva (cabotegravir and rilpivirine).

The FDA also approved Vocabria (cabotegravir) which is an oral tablet formulation of Cabenuva. Voacabria should be taken in combination with oral rilpivirine (Edurant) for one month prior to starting treatment with Cabenuva to ensure the medications are well-tolerated before switching to the extended-release injectable formulation.

Cabenuva is indicated as a complete regimen for the treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies…


Healthcare social media strategy and tactics for 2021
Healthcare social media strategy and tactics for 2021
… 2021 healthcare social media strategy and tactics …

New social media opportunities and challenges lay ahead for healthcare marketers in 2021

John G. Baresky

Social media is a key element of many healthcare marketing strategies. Many analytical models, usage reports and other sources of measurement profile the most popular trending topics and the times of peak volume when the highest level of traffic is present on specific social media platforms.

While these provide a glimpse into the wilderness of social media, they are not enough to guide a revenue-effective healthcare social media strategy. There are further strategies and methods to refine them and a 4-phase process enables healthcare marketing professionals to precisely zero in on and productively engage their target personas.


Walgreens and AmerisourceBergen: $6.5 Billion Alliance Health Deal
Walgreens and AmerisourceBergen: $6.5 Billion Alliance Health Deal
… Walgreens Boots Alliance Spins Off Alliance Health Wholesale Business Unit For $65. Billion …

Walgreens sells majority stake of its Alliance Healthcare business unit to AmerisourceBergen

John G. Baresky

Walgreens Boots Alliance (NASDAQ: WBA) is selling a majority stake of Alliance Healthcare to AmerisourceBergen for $6.275 billion in cash and two million shares of AmerisourceBergen common stock.

The deal benefits Walgreens and AmerisourceBergen in several ways. Walgreens streamlines its business model to focus its attention on retail, mail order and specialty pharmacy plus drive the expansion of its in-store primary care clinic initiative. The company gains a substantial amount of cash plus adds to its already substantial holdings of AmerisourceBergen stock.

By adding Alliance Healthcare to its organization, AmerisourceBergen fortifies its competitive position against Cardinal, Henry…


NorthShore University HealthSystem Buys Northwest Community Healthcare
NorthShore University HealthSystem Buys Northwest Community Healthcare
… NorthShore University HealthSystem Acquires Northwest Community Healthcare …

Chicago healthcare marketplace competition heats up

John G. Baresky

NorthShore University HealthSystem has formally completed its acquisition of Northwest Community Healthcare. NorthShore University HealthSystem (NSUHS or “NorthShore”) is based in the Chicago suburb of Evanston Northwest Community Healthcare (NWCH or “Northwest Community”) is located in the Chicago suburb of Arlington Heights.

NWCH was established in 1959 and has grown as the surrounding communities it supports became more densely populated. Its location and patient population made it very attractive for Chicago area health systems and others to consider buying them. Northwest Community attributes include:

  • 509-bed hospital
  • Approximately 4,000 employees
  • 1,200 doctors on staff at more than 40…

Urovant’s new overactive bladder (OAB) drug Gemtesa (vibegron) is approved by the FDA
Urovant’s new overactive bladder (OAB) drug Gemtesa (vibegron) is approved by the FDA
… Urovant’s New Overactive Bladder Drug Gemtesa (vibegron) is FDA approved …

Urovant’s First FDA Approved Drug

John G. Baresky

The U.S. Food and Drug Administration (FDA) has approved Urovant Sciences' new drug Gemtesa (vibegron) for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence (UUI), urgency and urinary frequency in adults.

Gemtesa is an oral pharmaceutical agent that is produced in pill form and available by prescription only. It is a beta-3 adrenergic receptor (β3) agonist. Founded in 2016, it is Urovant’s (NASDAQ: UROV) first new drug approval.

The last new OAB drug approved by the FDA is Astellas’ (OTCMKTS: ALPMY) Myrbetriq™ (mirabegron). Myrbetriq was launched in 2012 and like Gemtesa is available…


Philips acquires BioTelemetry for $2.5 billion
Philips acquires BioTelemetry for $2.5 billion
… Philips Expands Its Remote Patient Care Monitoring Business WIth BioTelemetry Acquisition …

Philips expedites business strategy to advance in remote patient monitoring

John G. Baresky

Royal Philips NV or “Philips” (NYSE: PHG) is acquiring BioTelemetry (NASDAQ: BEAT) for $2.5 billion to accelerate its business plan to be a leader in home care patient monitoring. Philips recognizes the significant opportunities and escalating growth of telehealth (or telemedicine!) triggered by the COVID-19 pandemic and advanced capabilities of new technology and cloud computing.

There has been a gold rush of mergers and acquisitions, new product development and large-scale business development deals throughout the remote patient monitoring technology sector during 2020. Amazon, Apple, Google and Teladoc are just some of the companies developing wearable and remote…


Boerhinger Ingelheim grows cancer care product line by buying NBE Therapeutics
Boerhinger Ingelheim grows cancer care product line by buying NBE Therapeutics
… Boerhinger Ingelheim buys oncology therapy innovator NBE Therapeutics …

NBE Therapeutics’ novel oncology clinical technology is sought by Boehringer Ingelheim to boost new cancer drug development pipeline

John G. Baresky

Privately-held global pharmaceutical leader Boehringer Ingelheim has announced it is acquiring NBE Therapeutics for $1.5 billion. Headquartered in Basel, Switzerland, NBE was founded in 2012 and specializes in the development of new, advanced oncology therapies based on highly differentiated antibody-drug conjugate (ADC) elements.

NBE-Therapeutics’ iADC platform is a significant clinical asset that Boehringer Ingelheim covets as it will fortify their ability to create new tumor-targeting therapies they can fully develop and commercialize. The strategic oncology-focused acquisition is the third in as many years for Boehringer Ingelheim as it follows these earlier deals:

  • $398 million for AMAL Therapeutics…

Orladeyo (berotralstat) is FDA indicated to treat Hereditary Angioedema
Orladeyo (berotralstat) is FDA indicated to treat Hereditary Angioedema
… FDA Approves Orladeyo (berotralstat) for Hereditary Angioedema patients …

A new cardiovascular agent treats Hereditary Angioedema (HAE)

John G. Baresky

The U.S. Food and Drug Administration (FDA) has issued BioCryst Pharmaceuticals approval for its new drug, Orladeyo (berotralstat), with an indication to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older.

Orladeyo, a plasma kallikrein inhibitor, is available by prescription only and is produced in orally-administered 150mg capsules that are taken once daily. It works by decreasing the activity of plasma kallikrein in patients diagnosed with HAE.

BioCryst Pharmaceuticals may have an important brand and market access strategy over its rivals with Orladeyo…

Bare Sky Marketing — Healthcare Content Writing

Authentic, fact-based healthcare content marketing writing for medical, business, academic, patient and consumer audiences https://www.BareSkyMarketing.com/

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store